A Phase 3 interventional study of Ganoderma Spore Lipids and Placebo in Gastrointestinal Neoplasms, sponsored by Xiaonan Cui. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-05-30.
Sponsored by Xiaonan Cui · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Gastrointestinal Neoplasms with a site in China — 44 open to participants now, 51 under way, 6 of them phase 3. Gastrointestinal Neoplasms · China.
Among the 110 studies in Gastrointestinal Neoplasms with a site in China, this one is the 63rd largest by planned enrollment of the 88 interventional ones that give a count, is one of 5 that started in 2016, is one of 11 in phase 3, and was the 14th registered.
698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.
Browse Gastrointestinal Neoplasms studies →44 of the 110 studies in Gastrointestinal Neoplasms with a site in China are open now. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 45–74 · Healthy volunteers
Hunan Cancer Hospital · Sites in China
Ages 45–74 · Healthy volunteers
Changhai Hospital · Sites in China
Ages 18+
Peking University Cancer Hospital & Institute · Sites in China
Ages 18+
Beijing GoBroad Hospital · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 26 · Phase 3 12 · Phase 4 4
First in 2005; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 73 across 497 interventional studies indexed under Gastrointestinal Neoplasms.
Median enrollment 120 across the 88 interventional studies, 500 across the 22 observational. Of the 29 that completed or were terminated, 6 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 110 have an industry lead sponsor. The 10 most frequent:
Xiaonan Cui is the lead sponsor of 4 studies on the registry; none are open to participants now.
Xiaonan Cui has 3 studies filed under Gastrointestinal Neoplasms — fewer than ten, so there is no comparison to draw.
16 of the studies in Gastrointestinal Neoplasms with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06966232Phase 3Sun Yat-sen UniversityProphylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers | 2027-05-15 |
| NCT05252078Jiangxi Provincial Cancer HospitalAnlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients | 2026-11 |
| NCT05321316Peking University Cancer Hospital & InstituteNectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors | 2026-12 |
| NCT06881043The First Hospital of Jilin UniversityThe Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer | 2026-12-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 110 studies in Gastrointestinal Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase III double-blind randomized clinical trial on the effects of ganoderma spore lipids to the immunological response in patients with G.I. Cancers. The trial is randomized, double-blind. Cancer patients are diagnosed based on pathology or cell biology. Patients are randomized into 2 groups: both groups receive chemotherapy. Either group receives ganoderma spore lipids or placebo capsules 600mg three times a day (TID) in addition to the chemotherapy. Clinical evaluation includes chemotherapy drug toxicities, life quality improvement. Blood biochemistry tests mainly include malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), adrenaline, nor-adrenaline, tumor necrosis factor (TNF)-α, interleukin (IL)-1b, interleukin (IL)-6, cell flow cytometry on Th1, Th2, Th17, Treg cytokines, as well as serum cortisol, estradiol (female), progesterone (female), testosterone (male), etc.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Past treatment:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Form: Capsule Dosage and frequency: This group receives ganoderma spore lipids capsules 600mg TID in addition to the chemotherapy. Duration: 6 chemotherapy cycles.
Drug: Ganoderma Spore Lipids · Drug: Chemotherapy
Form: Capsule Dosage and frequency: This group receives placebo capsules 600mg TID in addition to the chemotherapy. Duration: 6 chemotherapy cycles.
Drug: Placebo · Drug: Chemotherapy
Also known as: G. SPORE LIPIDS
Adverse Events: neutropenia, leukopenia, thrombocytopenia, anemia, nausea, vomit, fatigue, loss of appetite.
Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).
Assessing the quality of life(QOL) in 5 grades and recording: appetite, mental state, sleep, fatigue, pain, attitude towards treatment, daily life ability, treatment of severity of side effects.
Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).
Th1/Th2, Th17/Treg in blood.
Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).
Interleukin(IL)-1b, interleukin(IL)-6, tumor necrosis factor(TNF)-α in blood.
Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).
Estradiol (female), progesterone (female), testosterone (male) in blood.
Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).
Vanillylmandelic acid (VMA) in urine.
Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of May 2016 and a primary completion of May 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiaonan Cui